Table 1.
Average vaccine efficacy (VEavg) against incident HPV infection for years 2–11
| HPV types | Unvaccinated (HAV or UCG) |
HPV-vaccinated (3-dose) |
HPV-vaccinated (1-dose) |
VEavg expressed in % (95% CI) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of infection | Person-years | Rate of infection (%) | No. of infection | Person-years | Rate of infection (%) | No. of infection | Person-years | Rate of infection (%) | 3-dose | 1-dose | |||
| A priori cross-protected HPV types | |||||||||||||
| HPV31 | 315 | 12 643 | 2.5 | 96 | 10 657 | 0.9 | 10 | 662 | 1.5 | 64.1 (54.9 to 71.3) | 37.7 (−23.1 to 68.4)§ | ||
| HPV33 | 95 | 12 981 | 0.7 | 54 | 10 773 | 0.5 | 3 | 672 | 0.4 | 31.3 (4.0 to 50.8) | 37.1 (−96.8 to 79.9) | ||
| HPV45 | 224 | 12 828 | 1.7 | 38 | 10 756 | 0.4 | 3 | 674 | 0.4 | 79.6 (71.3 to 85.5) | 74.6 (20.8 to 91.9) | ||
| HPV31/33/45 | 562 | 12 324 | 4.6 | 170 | 10 509 | 1.6 | 14 | 658 | 2.1 | 64.4 (57.7 to 70.0) | 54.4 (21.0 to 73.7) | ||
| Vaccine-targeted HPV types | |||||||||||||
| HPV16 | 386 | 12 407 | 3.1 | 63 | 10 641 | 0.6 | 4 | 671 | 0.6 | 80.9 (74.8 to 85.5) | 79.3 (45.4 to 92.1) | ||
| HPV18 | 238 | 12 795 | 1.9 | 26 | 10 774 | 0.2 | 0 | 676 | 0.0 | 87.1 (80.6 to 91.4) | 100.0 (76.0 to 100.0)‡ | ||
| HPV16/18 | 569 | 12 158 | 4.7 | 88 | 10 573 | 0.8 | 4 | 671 | 0.6 | 82.0 (77.3 to 85.7) | 86.4 (64.1 to 94.8) | ||
| Other HPV types | |||||||||||||
| HPV35 | 147 | 12 910 | 1.1 | 94 | 10 741 | 0.9 | 5 | 672 | 0.7 | 23.2 (0.3 to 40.8) | 31.6 (−64.2 to 71.5) | ||
| HPV39 | 250 | 12 762 | 2.0 | 204 | 10 555 | 1.9 | 9 | 660 | 1.4 | 1.4 (−18.5 to 17.9) | 29.5 (−35.0 to 63.2) | ||
| HPV51 | 389 | 12 619 | 3.1 | 342 | 10 390 | 3.3 | 15 | 651 | 2.3 | −6.4 (−22.8 to 7.8) | 20.5 (−30.9 to 51.7) | ||
| HPV52 | 450 | 12 476 | 3.6 | 367 | 10 338 | 3.6 | 29 | 642 | 4.5 | 2.2 (−12.1 to 14.7) | −33.5 (−89.7 to 6.0) | ||
| HPV56 | 248 | 12 769 | 1.9 | 261 | 10 559 | 2.5 | 11 | 663 | 1.7 | −26.7 (−50.6 to -6.7) | 10.9 (−59.7 to 50.3) | ||
| HPV58 | 252 | 12 785 | 2.0 | 163 | 10 610 | 1.5 | 15 | 658 | 2.3 | 21.2 (4.2 to 35.3) | −17.4 (−93.5 to 28.7)§ | ||
| HPV59 | 206 | 12 897 | 1.6 | 176 | 10 674 | 1.6 | 14 | 660 | 2.1 | −4.7 (−27.8 to 14.3) | −32.3(−123.8 to 21.8) | ||
| Other oncogenic HPVs* | 1291 | 11 079 | 11.7 | 1078 | 9107 | 11.8 | 63 | 571 | 11.0 | −1.7 (−9.9 to 5.9) | 4.4 (−22.4 to 25.4) | ||
| HPV6/11 | 202 | 12 866 | 1.6 | 184 | 10 649 | 1.7 | 9 | 669 | 1.3 | −10.6 (−34.7 to 9.2) | 11.8 (−69.1 to 54.0) | ||
| Other nononcogenic HPVs† | 1446 | 11 019 | 13.1 | 1233 | 9027 | 13.7 | 77 | 575 | 13.4 | −5.1 (−13.0 to 2.2) | −1.1 (−26.0 to 18.8) | ||
*
Other oncogenic HPVs are HPV35, -39, -51, -52, -56, -58, and -59. HAV = hepatitis A virus-vaccinated control group; UCG = unvaccinated control group.
†
Other nononcogenic HPVs are HPV34, -40, -42, -43, -44, -53, -54, -66, -68, -70, -73, and -74.
‡
Confidence intervals (CI) were calculated using the two-step approach, which did not account for dependence.
§
P 1vs3 = .11; all other P1vs3 ≥ .15.